Comparing SG&A Expenses: Pfizer Inc. vs Genmab A/S Trends and Insights

SG&A Expenses: A Tale of Two Giants

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry leaders is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Pfizer Inc. and Genmab A/S from 2014 to 2023.

Pfizer Inc.: A Steady Giant

Pfizer, a stalwart in the pharmaceutical world, consistently allocated significant resources to SG&A, averaging around $14 billion annually. Despite fluctuations, Pfizer's expenses remained relatively stable, reflecting a robust strategy in maintaining market presence and operational efficiency.

Genmab A/S: A Rising Star

In contrast, Genmab A/S exhibited a remarkable growth trajectory, with SG&A expenses skyrocketing from approximately $80 million in 2014 to over $3 billion in 2023. This 40-fold increase underscores Genmab's aggressive expansion and investment in market penetration.

Conclusion

This comparative analysis highlights the diverse strategies of these pharmaceutical giants, offering insights into their operational priorities and market dynamics.